Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 13/20 | 0.43 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.38 |
| ▸ | PLA2G2A | P14555 | 3/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6489538 | 0.90 | MCL1 (0.42) | MCL1BCL2L1PLA2G2AFFAR4ALDH1A1 | |
| SCHEMBL6502360 | 0.90 | PABPC1 (0.39) | MCL1PLA2G2AALDH1A1 | |
| SCHEMBL6490678 | 0.89 | MCL1 (0.41) | MCL1BCL2L1PLA2G2AFFAR4 | |
| SCHEMBL6497809 | 0.88 | MCL1 (0.41) | MCL1FFAR4ALDH1A1MAPT | |
| SCHEMBL6490634 | 0.85 | MCL1 (0.46) | MCL1BCL2L1PLA2G2AFFAR4 | |
| SCHEMBL6501595 | 0.83 | MCL1 (0.46) | MCL1BCL2L1PLA2G2AFFAR4 | |
| SCHEMBL6488276 | 0.82 | PIK3C2B (0.50) | MCL1PLA2G2AFFAR4 | |
| SCHEMBL6503536 | 0.82 | MCL1 (0.46) | MCL1PLA2G2AFFAR4 | |
| SCHEMBL6489292 | 0.81 | MCL1 (0.38) | MCL1PLA2G2AALDH1A1MAPTHPGD | |
| SCHEMBL6501064 | 0.80 | PIK3C2B (0.38) | MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-01-20 | — | — | US | claimed |
| US-20050014812-A1 | Benzimidazole compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
| WO-2004108686-A2 | BENZIMIDAZOLE COMPOUNDS HAVING HYPOGLYCEMIC ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | SLC5A1, SLC5A2, G6PD | MCL1 806/4885BCL2L1 1036/4885PLA2G2A 4801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.